CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 9 enrolled
Drug / intervention
bevacizumabdrug
Likely dose
bevacizumab 0,05mlfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02015351
NCT02015351N/ACompleted
CompareCT.gov

Intravitreal Bevacizumab for the Treatment of Choroidal Neovascularization in Vogt-Koyanagi-Harada Disease - A Prospective Study

University of Sao Paulo·interventional·Posted Dec 19, 2013·Updated Jan 5, 2022

In Brief

A clinical study evaluating bevacizumab for Choroidal Neovascularization. Completed, enrolled 9 participants across 1 site.

Detailed Summary

Efficacy of monthly intravitreal anti-vascular endothelial growth factor (VEGF) associated to systemic immunosuppression in patients with Vogt-Koyanagi-Harada Disease and choroidal neovascularization. Minimum follow-up 12 months. Endpoints: 6 and 12 months of follow-up. Outcome measures: improvement of VA, decrease in central foveal thickness as measured by Optical Coherence Tomography (OCT) and absence of intra/subretinal fluid.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChoroidal Neovascularization
CountriesBrazil
CollaboratorsFundação de Amparo à Pesquisa do Estado de São Paulo

Timeline

N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedDec 19, 2013
Enrollment StartSep 1, 2012
Primary CompletionOct 1, 2017
Study CompletionOct 1, 2018
TodayJul 2, 2026
Enrollment to primary: 5.1 yearsPosted 12.5 years ago

Interventions

bevacizumabdrug

Injection technique: After lid speculum insertion and irrigation of the conjunctiva with 5% povidone-iodine, 0,05ml of bevacizumab will be inserted through the pars plana 3.5mm to 4.0mm posterior to the surgical limbus using a 30 gauge needle. After injection, topical antibiotics will be immediately applied in the injected eye. Immunosuppression: Corticosteroids will be prescribed (1mg/Kg/d) with tapering along 5 months. Immunosuppressive drug of choice is cyclosporine (3-5mg/Kg/d). In case of contraindication to cyclosporine use, azathioprine or mycophenolate mofetil will be prescribed.